Quick Dispatch:
Your glp-1 roche Roche Bets Splits in Obesity Market Will Open Door to New Entrants orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp-1 roche Roche Bets Splits in Obesity Market Will Open Door to New Entrants ships.
Need Help?
Questions about glp-1 roche Roche Bets Splits in Obesity Market Will Open Door to New Entrants, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp-1 roche Roche Bets Splits in Obesity Market Will Open Door to New Entrants in your area.
Roche Enters the GLP-1 Obesity Drug Market... Spotlight on Amylin Combination Strategy
27.05
How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments
20.64
⚡️ 𝗥𝗼𝗰𝗵𝗲 𝗷𝘂𝘀𝘁 𝗽𝗼𝘀𝘁𝗲𝗱 𝗣𝗵𝗮𝘀𝗲 𝟮 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗱𝗮𝘁𝗮 𝘁𝗵𝗮𝘁 𝗿𝗶𝘃𝗮𝗹 𝗭𝗲𝗽𝗯𝗼𝘂𝗻𝗱... 𝗬𝗲𝗮𝗿𝘀 𝗹𝗮𝘁𝗲 𝘁𝗼 𝗮 $𝟭𝟬𝟬𝗕 𝗿𝗮𝗰𝗲. Roche has released Phase 2 results for CT-388, a dual GLP-1/GIP injectable obesity
28.52
Roche's head of cardiovascular disease dissects GLP-1 drug trial results
24.64
Roche Oral GLP-1 Agonist Scores in Early Trial
23.13
GLP-1-based therapies for diabetes, obesity and beyond
27.50
![Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://a.storyblok.com/f/176343/1920x1281/9879d12165/roche_270354.jpeg)
Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
25.12
